Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of PWT-143 in healthy subjects
NCT02521389Phase 1Completed
- Sponsor
- MEI Pharma
- Start
- Jun 2015
- Primary completion
- Feb 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of zandelisib in hematologic malignancy (2 arms), sponsored by MEI Pharma. Primary endpoint: Number of participants with and types of Adverse Events at 5 months. Started Jun 2015; status: completed.
02
Drugs
zandelisib
03
Conditions
hematologic malignancy
Beyond the preview
Go deeper on NCT02521389.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02521389.